Patent intelligence · US
US 11649251
Substituted inhibitors of menin-MLL and methods of use
Substituted inhibitors of menin-MLL and methods of use
Patent details — US 11649251
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 16, 2023
- Expiration
- May 11, 2043
- Applicant
- Kura Oncology, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/5355, A61K45/06, A61K9/0019
Quick answer
US 11649251 (Substituted inhibitors of menin-MLL and methods of use) is held by Kura Oncology, Inc.. Status: granted. Granted May 16, 2023. Expires May 11, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kura Oncology, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/5355, A61K45/06, A61K9/0019, A61K9/0053, A61P
More from Kura Oncology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 11649251?
US 11649251 (Substituted inhibitors of menin-MLL and methods of use) is held by Kura Oncology, Inc.. Status: granted. Granted May 16, 2023. Expires May 11, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11649251?
Kura Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 11649251 expire?
Our index shows an expiration date of May 11, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.